Clinical Trials Logo

Ischemia clinical trials

View clinical trials related to Ischemia.

Filter by:

NCT ID: NCT01100385 Completed - Stroke Clinical Trials

TomVasc - Vascular Effects of Tomato Extract

TomVasc
Start date: February 2010
Phase: N/A
Study type: Interventional

Does tomato extract improve blood vessel function in healthy people and people with cardiovascular disease? Atherosclerosis ('furring' of the arteries) affects the functioning of blood vessels, narrowing and eventually blocking them, causing conditions like heart attack and stroke. The Mediterranean diet, which is rich in tomatoes and tomato-based products, has been shown to be associated with a reduced risk of blood vessel damage. In this double blind, placebo-controlled randomised study, the investigators will investigate whether a food supplement containing a standardised extract of tomato improves blood vessel function in both healthy people (aged 40-80), and people with a history of cardiovascular disease. The food supplement is on sale to the public, and the investigators are testing the standard dose. Approximately 72 people will take part at the Clinical Pharmacology Unit at the ACCI Building, Cambridge University Hospitals NHS Trust. After they have passed screening tests, participants will be allocated by chance to receive either the tomato extract product (Ateronon), or a matching placebo (a dummy capsule with no active ingredients), which they will take once a day for 8 weeks. At the beginning and end of the treatment period, the investigators will test blood vessel stiffness using an ECG machine and external probe. The investigators will also measure forearm blood flow, which involves infusing 3 separate agents that affect how the lining of the blood vessel wall works, and helps to assess whether this is affected by the study treatment. Blood tests will also be used to look at how the food supplement is working and its effects on cholesterol and markers of inflammation. Including the screening period, and a follow-up telephone call two weeks after the end of treatment, participants will be in the study for 14 weeks.

NCT ID: NCT01098981 Terminated - Clinical trials for Acute Ischemic Stroke

Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke

CLOTBUST-ER
Start date: May 2013
Phase: Phase 3
Study type: Interventional

This is a randomized, placebo-controlled, phase 3 clinical trial to evaluate the efficacy and safety of transcranial ultrasound (US) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.

NCT ID: NCT01097967 Active, not recruiting - Ischemic Stroke Clinical Trials

Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy

SAS-CARE
Start date: July 2010
Phase: Phase 4
Study type: Interventional

The study aims to observe the short term effect (3-month) of sleep disordered breathing (SDB) on cardiovascular parameters, heart rate variability, endothelial function and surrogate markers of atherosclerosis after acute cerebrovascular events (ACE). The long-term effect (6-24-month) of Continuous Positive Airway Pressure (CPAP) on clinical vascular outcome, cardiovascular parameters, evolution of surrogate of atherosclerosis heart rate variability and endothelial function after ACE is observed over 24 months. A preventive effect of CPAP therapy on cerebro-vascular events in patients with moderate-severe obstructive SDB without sleepiness after ictus or transient ischaemic attack will be evaluated.

NCT ID: NCT01088672 Completed - Ischemic Stroke Clinical Trials

Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)

TREVO
Start date: February 2010
Phase: Phase 4
Study type: Interventional

To determine the revascularization rate of the CE-marked Trevo device in large vessel occlusions in ischemic stroke patients. - Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro interventional procedure.

NCT ID: NCT01086228 Completed - Clinical trials for Coronary Artery Disease

XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan

Start date: March 2010
Phase: N/A
Study type: Observational

The objectives of this post-marketing surveillance, conducted in Japan, is to know the frequency, type and degree of device malfunction, to assure the safety of the medical device, and to collect information on evaluation of the efficacy and safety.

NCT ID: NCT01078324 Completed - Colitis, Ischemic Clinical Trials

Study of Ischemic Colitis Compared to Other Diagnoses in Patients With Lower Gastrointestinal Bleeding

Start date: December 1997
Phase: N/A
Study type: Observational

The purpose of this study is to study the demographic,laboratory,endoscopic, and outcomes of ischemic colitis patient presented with severe lower gastrointestinal bleeding compared to other diagnoses.

NCT ID: NCT01076920 Completed - Clinical trials for Left Ventricular Dysfunction

Mesenchymal Stem Cells and Myocardial Ischemia

MESAMI
Start date: October 2009
Phase: Phase 1/Phase 2
Study type: Interventional

Ischemic cardiomyopathies are a leading cause of death in both men and women. When a person has a heart attack, blood is unable to reach a certain area of the heart, and if the blood supply is not re-established quickly, that area of the heart can suffer permanent damage. While recovery from a heart attack can be managed through medications and lifestyle changes, these treatments can not reverse the all damage to the heart. Current research is focusing on the development of cell-based therapies using stem cells to repair organs that have been irreversibly damaged by disease. A specific form of stem cells, called adult mesenchymal stem cells (MSCs), has shown promise for heart repair. This study will evaluate the safety of injecting MSCs directly into the heart to repair and restore heart function in people who have had a heart attack and who have chronic myocardial ischemia with heart failure.

NCT ID: NCT01075776 Withdrawn - Clinical trials for Ischaemia-reperfusion (IR) Injury

The Effects of C-type Natriuretic Peptide on Human Forearm Blood Vessels

Start date: January 2020
Phase: N/A
Study type: Interventional

To determine the effects of whether increasing CNP concentrations slightly above normal will improve the functioning of blood vessels after the interruption in the flow of blood. In this study we are looking at the function of the blood vessels of the forearm, as a substitute for those in the heart

NCT ID: NCT01072669 Completed - Ischemia Clinical Trials

Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet

ambrisentan
Start date: February 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effectiveness of a drug called ambrisentan, approved by the FDA for use in pulmonary hypertension (a condition where there is increased pressure in the right side of the heart) in scleroderma patients, to see if this medicine may be beneficial in relieving and/or preventing Raynaud's flares in you and other patients like you. This medicine may have some short-term and long-term benefits in persons with scleroderma

NCT ID: NCT01071408 Completed - Ischemic Stroke Clinical Trials

Trial of a Secondary Stroke Prevention Program

Start date: March 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether an outpatient program can reduce the risk of recurrent stroke.